These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23526664)

  • 1. Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.
    Rennick A; Kalakeche R; Seel L; Shepler B
    Pharmacotherapy; 2013 Jun; 33(6):683-90. PubMed ID: 23526664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niacin and related compounds for treating hyperphosphatemia in dialysis patients.
    Berns JS
    Semin Dial; 2008; 21(3):203-5. PubMed ID: 18363600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients.
    Aramwit P; Srisawadwong R; Supasyndh O
    J Nephrol; 2012; 25(3):354-62. PubMed ID: 21748722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
    El Borolossy R; El Wakeel LM; El Hakim I; Sabri N
    Pediatr Nephrol; 2016 Feb; 31(2):289-96. PubMed ID: 26420678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.
    Shahbazian H; Zafar Mohtashami A; Ghorbani A; Abbaspour MR; Belladi Musavi SS; Hayati F; Lashkarara GR
    Nefrologia; 2011; 31(1):58-65. PubMed ID: 21270914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia].
    Restrepo Valencia CA; Cruz J
    Nefrologia; 2008; 28(1):61-6. PubMed ID: 18336133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niacin and Chronic Kidney Disease.
    Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
    J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of nicotinamide to treat hyperphosphatemia in dialysis patients.
    Lenglet A; Liabeuf S; Guffroy P; Fournier A; Brazier M; Massy ZA
    Drugs R D; 2013 Sep; 13(3):165-73. PubMed ID: 24000048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended release nicotinic acid - a novel oral agent for phosphate control.
    Sampathkumar K; Selvam M; Sooraj YS; Gowthaman S; Ajeshkumar RN
    Int Urol Nephrol; 2006; 38(1):171-4. PubMed ID: 16502077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary glands: a new player in phosphorus metabolism.
    Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
    J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sevelamer carbonate.
    Barna MM; Kapoian T; O'Mara NB
    Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotinic acid and related compounds: A meta-analysis of their use for hyperphosphatemia in dialysis patients.
    Liu X; Yang R; Dai B; Zhang H; Wang J; Ma N
    Medicine (Baltimore); 2018 Mar; 97(12):e0117. PubMed ID: 29561409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.
    Bostom AG; Maclean AA; Maccubbin D; Tipping D; Giezek H; Hanlon WA
    J Clin Lipidol; 2011; 5(4):281-7. PubMed ID: 21784373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients.
    Shin S; Lee S
    Ther Clin Risk Manag; 2014; 10():875-83. PubMed ID: 25342908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis.
    Hung KY; Liao SC; Chen TH; Chao MC; Chen JB
    Ther Apher Dial; 2013 Feb; 17(1):72-7. PubMed ID: 23379497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotinamide and phosphate homeostasis in chronic kidney disease.
    Ginsberg C; Ix JH
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):285-91. PubMed ID: 27219041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients.
    Young DO; Cheng SC; Delmez JA; Coyne DW
    Perit Dial Int; 2009; 29(5):562-7. PubMed ID: 19776051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.